Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EMKXQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
37222285 ADC 1
|
|||||
| Synonyms |
ADC 1
Click to Show/Hide
|
|||||
| Organization |
Technical University of Denmark; University of Copenhagen; Abzena Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Auri E
|
Payload Info | ||||
| Linker Name |
sulfatase-responsive linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.49 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Next, the dose dependent cytotoxicity of ADC1 was investigated in HER2-positive (BT474 and SK-BR3) and HER2-negative (MCF-7) breast cancer cell lines. The potency of ADC1 was compared to the FDA approved ADC Kadcyla®. ADC1 proved to be highly potent in both BT474 and SK-BR3 cell lines while having negligible toxicity in MCF-7 cells, indicating neglectable extracellular linker cleavage (Fig. 4). We also observed that ADC 1 had a higher potency against BT-474 cells (IC50 = 0.49 nM) compared to Kadcyla (IC50 =1.06 nM) suggesting efficient intracellular linker cleavage and payload release.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||